Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001193805-17-003257
Filing Date
2017-10-10
Accepted
2017-10-10 07:30:32
Documents
1
Group Members
DEERFIELD INTERNATIONAL MASTER FUND, L.P.DEERFIELD MANAGEMENT COMPANY, L.P.DEERFIELD MGMT, L.P.DEERFIELD PARTNERS, L.P.DEERFIELD SPECIAL SITUATIONS FUND, L.P.

Document Format Files

Seq Description Document Type Size
1 e617373_sc13g-aclaris.htm SC 13G 126828
  Complete submission text file 0001193805-17-003257.txt   128310
Mailing Address 780 THIRD AVENUE 37TH FLOOR NEW YORK NY 10017
Business Address
Flynn James E (Filed by) CIK: 0001352546 (see all company filings)

Type: SC 13G

Mailing Address SUITE 400, 101 LINDENWOOD DRIVE MALVERN PA 19355
Business Address SUITE 400, 101 LINDENWOOD DRIVE MALVERN PA 19355 484-321-5554
Aclaris Therapeutics, Inc. (Subject) CIK: 0001557746 (see all company filings)

EIN.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-89137 | Film No.: 171128609
SIC: 2834 Pharmaceutical Preparations